3/10/2008
Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity

1/22/2008
ANAVEX outlines
corporate milestones,
drug advancement
plans for 2008

12/17/2007
Anavex strengthens
Board of Directors

more